中国卫生产业
中國衛生產業
중국위생산업
CHINA HEALTH INDUSTRY
2014年
30期
32-33,36
,共3页
骨化三醇%继发性甲状旁腺功能亢进%尿毒症%冲击治疗
骨化三醇%繼髮性甲狀徬腺功能亢進%尿毒癥%遲擊治療
골화삼순%계발성갑상방선공능항진%뇨독증%충격치료
Calcitriol%Secondary hyperparathyroidism%Uremia%Shock therapy
目的：采用骨化三醇口服冲击治疗继发性甲旁亢患者，观察其疗效和安全性。方法将38例符合标准的患者随机分为对照组（骨化三醇0.25ug qn）和治疗组（骨化三醇2.0ug biw）各19例,两组患者均禁服钙制剂,予钙浓度1.5 mmol/L的碳酸氢盐透析液进行血液透析及相关治疗,对照组骨化三醇常规量口服,治疗组骨化三醇冲击量口服，连续治疗12周，对比两组患者血清钙、磷和甲状旁腺激素指标和不良反应的差异性。结果对照组治疗前后血钙、磷、钙磷乘积无明显变化(P>0.05),甲状旁腺激素在治疗后由（736.63±152.38）降至（714.36±172.55），呈轻度下降,但P>0.05,无统计学意义。治疗组治疗后与自身治疗前比较血钙、血磷、钙磷乘积无显著变化(P>0.05),而甲状旁腺激素由（713.37±154.33） pg/mL降至（321.45±98.72） pg/mL，呈明显下降(P<0.01)。结论采用骨化三醇冲击治疗，能有效控制尿毒症继发性甲旁亢，并且不良反应少，安全可行，值得临床推广。
目的：採用骨化三醇口服遲擊治療繼髮性甲徬亢患者，觀察其療效和安全性。方法將38例符閤標準的患者隨機分為對照組（骨化三醇0.25ug qn）和治療組（骨化三醇2.0ug biw）各19例,兩組患者均禁服鈣製劑,予鈣濃度1.5 mmol/L的碳痠氫鹽透析液進行血液透析及相關治療,對照組骨化三醇常規量口服,治療組骨化三醇遲擊量口服，連續治療12週，對比兩組患者血清鈣、燐和甲狀徬腺激素指標和不良反應的差異性。結果對照組治療前後血鈣、燐、鈣燐乘積無明顯變化(P>0.05),甲狀徬腺激素在治療後由（736.63±152.38）降至（714.36±172.55），呈輕度下降,但P>0.05,無統計學意義。治療組治療後與自身治療前比較血鈣、血燐、鈣燐乘積無顯著變化(P>0.05),而甲狀徬腺激素由（713.37±154.33） pg/mL降至（321.45±98.72） pg/mL，呈明顯下降(P<0.01)。結論採用骨化三醇遲擊治療，能有效控製尿毒癥繼髮性甲徬亢，併且不良反應少，安全可行，值得臨床推廣。
목적：채용골화삼순구복충격치료계발성갑방항환자，관찰기료효화안전성。방법장38례부합표준적환자수궤분위대조조（골화삼순0.25ug qn）화치료조（골화삼순2.0ug biw）각19례,량조환자균금복개제제,여개농도1.5 mmol/L적탄산경염투석액진행혈액투석급상관치료,대조조골화삼순상규량구복,치료조골화삼순충격량구복，련속치료12주，대비량조환자혈청개、린화갑상방선격소지표화불량반응적차이성。결과대조조치료전후혈개、린、개린승적무명현변화(P>0.05),갑상방선격소재치료후유（736.63±152.38）강지（714.36±172.55），정경도하강,단P>0.05,무통계학의의。치료조치료후여자신치료전비교혈개、혈린、개린승적무현저변화(P>0.05),이갑상방선격소유（713.37±154.33） pg/mL강지（321.45±98.72） pg/mL，정명현하강(P<0.01)。결론채용골화삼순충격치료，능유효공제뇨독증계발성갑방항，병차불량반응소，안전가행，치득림상추엄。
Objective To impact calcitriol oral treatment of patients with secondary near a port, to observe its efficacy and safety. Methods 38 patients with standard were randomly divided into control group (0.25 ug qn calcitriol) and treatment group (calcitriol 2.0 ug biw) 19 cases, two groups of patients were forbidden take calcium preparations, to calcium concentration tendency for 1.5/L bicarbonate dialysate in hemodialysis and related treatment, control amount of calcitriol conventional oral, treatment group of oral calcitriol impact quantity, continuous 12 weeks of treatment, compared two groups of patients with serum calcium, phosphorus and parathyroid hormone indexes and the difference of adverse reactions. Results In the control group before and after treatment the blood calcium, phosphorus and the calcium-phosphorus product no significant change (P> 0.05), parathyroid hormone after treat-ment by (736.63±152.38) to (714.36±172.55), a slight decline, but P>0.05, no statistical significance. Treatment group after treat-ment compared with before their treatment of blood calcium and blood phosphorus and the calcium-phosphorus product had no significant change (P>0.05), and parathyroid hormone by(713.37±154.33) pg/mL fell to (321.45±98.72) pg/mL, was significantly decreased (P<0.01). Conclusion Calcitriol shock treatment, can effectively control the uremia secondary near a port, and less ad-verse reaction, safe and feasible, is worth clinical promotion.
